Drug updated on 1/29/2024

Dosage FormTablet (oral; 3 mg, 4 mg, 5 mg)
Drug ClassKinase inhibitors
Ongoing and Completed


  • Indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy.

Product Monograph / Prescribing Information

Document TitleYearSource
Balversa (erdafitinib) Prescribing Information.2024Janssen Products, LP, Horsham, PA

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines

Document TitleYearSource
Bladder cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up.2021Annals of Oncology
Bladder cancer, version 3.20202020Journal of the National Comprehensive Cancer Network